Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | FRK | P42685 | 1/20 | 0.50 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.50 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.50 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636658 | 0.75 | FRK (0.44) | FRKCAMK2BCAMK2GCAMK2DALDH1A1 | |
| SCHEMBL3641127 | 0.75 | FRK (0.47) | FRKCAMK2BCAMK2GCAMK2DALDH1A1 | |
| SCHEMBL3633186 | 0.75 | HTT (0.51) | FRKCAMK2BCAMK2GCAMK2DALDH1A1 | |
| SCHEMBL3639533 | 0.75 | FRK (0.46) | FRKCAMK2BCAMK2GCAMK2D | |
| SCHEMBL3641307 | 0.74 | NAMPT (0.50) | FRKCAMK2BCAMK2GCAMK2D | |
| SCHEMBL3634267 | 0.74 | ALDH1A1 (0.59) | ALDH1A1 | |
| SCHEMBL3636468 | 0.74 | NAMPT (0.51) | FRKCAMK2BCAMK2GCAMK2DALDH1A1 | |
| SCHEMBL13743314 | 0.73 | CYP3A4 (0.52) | HRH3ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL3637976 | 0.73 | FRK (0.44) | FRKCAMK2BCAMK2GCAMK2DALDH1A1 | |
| SCHEMBL3638724 | 0.73 | FRK (0.44) | FRKCAMK2BCAMK2GCAMK2DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2167464-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | Abbott GmbH & Co. KG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008145616-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBOTT GMBH & CO. KG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | TAAR1 150/4885FRK 2372/4885CAMK2B 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.